Dr. Hsieh obtained a dual bachelor's degree in Chemistry and Chemical Engineering from National Chung Hsing University in 2009. Subsequently, he earned his master's degree in Chemical Engineering from the same institution in 2011. His academic journey culminated with the completion of his Ph.D. in Chemical Engineering at Virginia Tech in the United States in 2020. During his doctoral pursuit, his research efforts were dedicated to the advancement of microfluidic devices and their application in profiling epigenetic regulation within the contexts of cancer and human diseases.

Following the attainment of his doctorate, he embarked upon postdoctoral training at Stanford University School of Medicine, concentrating on the development of innovative single-cell technology and the investigation of drug resistance genes through the utilization of CRISPR-Cas9 screening technology.

Since February 2023, Dr. Hsieh has assumed the role of assistant professor within the Department of Chemical Engineering at National Taiwan University of Science and Technology. His current scholarly focus resides in the extraction of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from whole blood specimens utilizing microfluidic systems. This pioneering technology holds the promise of substantially advancing precision medicine and personalized healthcare endeavors.

Our laboratory is dedicated to the investigation of epigenetic regulation, cancer development, and precision medicine through the utilization of microfluidic systems. Our primary objective pertains to the advancement of novel technologies, characterized by both low-input requirements and high-throughput capabilities, to facilitate the comprehensive study of epigenetic regulation.